Academic Journal
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas
| العنوان: | Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas |
|---|---|
| المؤلفون: | Foss, Francine M., Horwitz, Steven M., Civallero, Mónica, Bellei, Mónica, Marcheselli, Luigi, Kim, Won Seog, Cabrera, María E., Dlouhy, Iván, Nagler, Arnon, Advani, Ranjana H., Pesce, Emanuela A., Ko, Young-Hyeh, Montoto, Silvia, Chiattone, Carlos, Moskowitz, Alison, Spina, Michele, Cesaretti, Marina, Biasoli, Irene, Federico, Massimo |
| المصدر: | American Journal of Hematology |
| بيانات النشر: | Wiley |
| سنة النشر: | 2020 |
| المجموعة: | Universidad de Chile: Repositorio académico |
| الوصف: | The T Cell Project was the largest prospective trial to explore the incidence, treatment patterns, and outcomes for T cell lymphomas. The rare subtypes of T cell lymphomas, including hepatosplenic T cell lymphoma (HSTCL), enteropathy associated T cell lymphoma (EATL), and peripheral gamma delta T cell lymphomas (PGDTCLs) are poorly represented in most studies and there is little data regarding treatment patterns. We report results from 115 patients with hepatosplenic (n = 31), enteropathy associated (n = 65), and PGDTCLs (n = 19). While anthracycline regimens were most commonly used as first line therapy, response rates ranged from 20%-40% and were suboptimal for all groups. Autologous stem cell transplantation was performed as a consolidation in first remission in a small number of patients (33% of HSTCL, 7% of EATL, and 12% of PGDTCL), and four patients with HSTCL underwent allogeneic stem cell transplantation in first remission. The progression free survival at 3 years ranged from 28%-40% for these rare subtypes, and the overall survival at 3 years was most favorable for PGDTCL (70%). These data highlight the need for novel treatment approaches for rare subtypes of T cell lymphomas and for their inclusion in clinical trials. ; Allos pharmaceuticals Associazione Angela Serra per la Ricerca sul Cancro Associazione Italiana per la Ricerca sul Cancro (AIRC) Fondazione Cassa di Risparmio di Modena Fondazione Italiana Linfomi Spectrum Pharmaceuticals NCI CCSG P30 CA008748 |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | American Journal of Hematology 2020;95:151–155.; https://repositorio.uchile.cl/handle/2250/178443 |
| DOI: | 10.1002/ajh.25674 |
| الاتاحة: | https://doi.org/10.1002/ajh.25674 https://repositorio.uchile.cl/handle/2250/178443 |
| Rights: | Attribution-NonCommercial-NoDerivs 3.0 Chile ; http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ |
| رقم الانضمام: | edsbas.B571397D |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/ajh.25674 |
|---|